Oracle (NYSE:ORCL) Price Target Lowered to $205.00 at Freedom Broker

Oracle (NYSE:ORCL) had its price objective dropped by Freedom Broker from $210.00 to $205.00 in a report issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the enterprise software provider’s stock. Freedom Broker’s price objective would indicate a potential upside of 41.88% from the company’s previous close.

A number of other analysts also recently commented on the company. Weiss Ratings downgraded Oracle from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, July 20th. Stifel Nicolaus decreased their price target on Oracle from $220.00 to $200.00 and set a “buy” rating for the company in a report on Friday. Stephens restated an “equal weight” rating and issued a $175.00 price objective on shares of Oracle in a research report on Friday. DA Davidson reaffirmed a “buy” rating and set a $225.00 price objective on shares of Oracle in a research note on Friday. Finally, Argus reiterated a “buy” rating and issued a $225.00 target price on shares of Oracle in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, thirty have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $253.95.

Oracle Stock Performance

Shares of NYSE:ORCL traded down $5.80 during midday trading on Monday, reaching $144.48. The company’s stock had a trading volume of 41,870,948 shares, compared to its average volume of 29,296,664. The company has a quick ratio of 1.12, a current ratio of 1.17 and a debt-to-equity ratio of 1.75. The stock has a fifty day moving average of $141.08 and a 200 day moving average of $160.52. Oracle has a twelve month low of $114.50 and a twelve month high of $329.50. The firm has a market capitalization of $416.18 billion, a PE ratio of 22.65, a P/E/G ratio of 1.10 and a beta of 1.74.

Oracle (NYSE:ORCL) last posted its earnings results on Thursday, September 10th. The enterprise software provider reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.74 by $0.18. The company had revenue of $19.34 billion during the quarter, compared to the consensus estimate of $19.13 billion. Oracle had a net margin of 26.36% and a return on equity of 47.43%. The firm’s quarterly revenue was up 29.6% on a year-over-year basis. During the same period in the previous year, the firm posted $1.47 earnings per share. Oracle has set its Q2 2027 guidance at 1.850-1.930 EPS and its FY 2027 guidance at 8.100-8.100 EPS. On average, equities analysts expect that Oracle will post 6.6 EPS for the current fiscal year.

Insiders Place Their Bets

In other Oracle news, Vice Chairman Jeffrey Henley sold 400,000 shares of Oracle stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $159.16, for a total transaction of $63,664,000.00. Following the sale, the insider owned 400,000 shares of the company’s stock, valued at $63,664,000. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 40.90% of the company’s stock.

Institutional Investors Weigh In On Oracle

A number of large investors have recently made changes to their positions in the stock. California State Teachers Retirement System increased its position in Oracle by 14,636.4% during the second quarter. California State Teachers Retirement System now owns 382,756,945 shares of the enterprise software provider’s stock worth $56,093,030,000 after purchasing an additional 380,159,589 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Oracle by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 37,734,944 shares of the enterprise software provider’s stock valued at $7,328,754,000 after acquiring an additional 665,374 shares during the period. Capital Research Global Investors boosted its stake in shares of Oracle by 29.3% in the fourth quarter. Capital Research Global Investors now owns 30,137,126 shares of the enterprise software provider’s stock valued at $5,874,070,000 after purchasing an additional 6,826,299 shares during the period. Norges Bank purchased a new position in shares of Oracle in the fourth quarter valued at approximately $4,336,031,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Oracle by 0.8% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,680,278 shares of the enterprise software provider’s stock valued at $2,151,395,000 after buying an additional 123,294 shares during the period. 42.44% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Oracle

Here are the key news stories impacting Oracle this week:

• Positive Sentiment: Oracle’s fiscal first-quarter results exceeded expectations, with revenue of $19.35 billion, up 29.6% year over year, and EPS of $1.92 versus the $1.74 consensus estimate. Management also issued fiscal 2027 guidance, supporting the long-term growth case. After Beating Expectations in Q1, Is Oracle Stock Due to Rally Higher?
• Positive Sentiment: Oracle reported strong demand for its cloud infrastructure: more than 300,000 GPUs were added during the quarter, while fleet utilization remained near 98%. The data point reinforces the potential for Oracle Cloud Infrastructure to benefit from sustained AI demand. Oracle’s AI Chips Ran 97.9% Utilized Last Quarter
• Positive Sentiment: Analysts remain divided but several maintain bullish views. Barclays raised its price target to $252, while Argus reaffirmed a Buy rating with a $225 target. Larry Ellison’s cancellation of a planned sale of up to $7.5 billion of Oracle shares also removed a potential source of selling pressure. Barclays resets Oracle stock price target
• Neutral Sentiment: Oracle Health launched a clinical AI agent for U.S. inpatient nurses, expanding the company’s healthcare AI offerings and potentially supporting future product adoption. Oracle Health Clinical AI Agent Helps Nurses
• Negative Sentiment: Investors are increasingly worried that Oracle’s roughly $90 billion AI-related capital-spending plan will pressure free cash flow and increase leverage. The company has reportedly begun another round of layoffs while investing heavily in data centers, raising concerns about restructuring costs and the economics of its AI expansion. Oracle begins a new round of layoffs
• Negative Sentiment: The Ellison transaction created uncertainty because the sale plan was filed and canceled within roughly one day. Some investors interpreted the reversal as unusual, while broader technology-sector weakness, interest-rate concerns and discussion of greater AI oversight added to selling pressure. Why Oracle Stock Fell Quickly Today

About Oracle

Oracle Corporation is a global enterprise technology company that develops and provides database software, cloud infrastructure, business applications and related technology services. Its offerings help organizations manage data, run applications, support business operations and build technology environments across on-premises, hybrid and cloud-based settings.

The company’s products include Oracle Database, MySQL, Java, Oracle Cloud Infrastructure and a broad portfolio of cloud applications for enterprise resource planning, financial management, human resources, supply chain management, customer experience and industry-specific operations.